Verubulin hydrochloride

TargetMol
Product Code: TAR-T13298
Supplier: TargetMol
CodeSizePrice
TAR-T13298-1mg1mg£108.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T13298-5mg5mg£173.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T13298-1mL1 mL * 10 mM (in DMSO)£185.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T13298-10mg10mg£229.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T13298-25mg25mg£402.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T13298-50mg50mg£567.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T13298-100mg100mg£777.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T13298-500mg500mg£1,508.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT

Overview

Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃

Images

1 / 1

Further Information

Bioactivity:
Verubulin hydrochloride is an agent of blood brain barrier permeable microtubule-disrupting, with potent and broad-spectrum cytotoxic activities,with potent anticancer activity in human MX-1 breast and other mouse xenograft cancer models.
CAS:
917369-31-4
Formula:
C17H18ClN3O
Molecular Weight:
315.8
Pathway:
Cytoskeletal Signaling
Purity:
0.9793
SMILES:
Cl.COc1ccc(cc1)N(C)c1nc(C)nc2ccccc12
Target:
Microtubule Associated

References

1. Kasibhatla S, et al. MPC-6827: a small-molecule inhibitor of microtubule formation that is not a substrate for multidrug resistance pumps. Cancer Res. 2007 Jun 15;67(12):5865-71. 2. Sirisoma N, et al. Discovery of N-(4-methoxyphenyl)-N,2-dimethylquinazolin-4-amine, a potent apoptosis inducer and efficacious anticancer agent with high blood brain barrier penetration. J Med Chem. 2009 Apr 23;52(8):2341-51.